Genprex Inc (GNPX)

Apr 01, 2025

Genprex Delays Yearly Report Filing - TipRanks

Apr 01, 2025

Apr 01, 2025

Genprex Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025

Apr 01, 2025

Genprex, Inc. SEC 10-K Report - TradingView

Apr 01, 2025

Mar 31, 2025

Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World

Mar 31, 2025

Mar 28, 2025

Genprex stock plunges to 52-week low of $0.27 - Investing.com

Mar 28, 2025

Mar 26, 2025

Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Genprex reports progress in lung cancer gene therapy - Investing.com India

Mar 26, 2025

Mar 26, 2025

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire

Mar 26, 2025

Mar 25, 2025

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Quantisnow

Mar 25, 2025

Mar 25, 2025

Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients - Stock Titan

Mar 25, 2025

Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025

Mar 14, 2025

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® De - GuruFocus.com

Mar 14, 2025

Mar 13, 2025

Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register

Mar 13, 2025

Mar 04, 2025

Genprex to Participate at BIO Europe Spring 2025 - StreetInsider.com

Mar 04, 2025

Mar 04, 2025

Can Genprex's Presence at BIO Europe Spring Attract New Partnership Opportunities? - Stock Titan

Mar 04, 2025

Feb 27, 2025

Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire

Feb 27, 2025

Feb 20, 2025

Genprex Strengthens Diabetes Focus with New License - TipRanks

Feb 20, 2025

Feb 19, 2025

Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria

Feb 19, 2025

Feb 19, 2025

Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Genprex explores non-viral gene therapy for diabetes - Investing.com India

Feb 19, 2025

Feb 19, 2025

Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan

Feb 19, 2025

Feb 18, 2025

Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria

Feb 18, 2025

Feb 18, 2025

Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com

Feb 18, 2025

Feb 18, 2025

Genprex announces advancement of its diabetes gene therapy program - TipRanks

Feb 18, 2025

Feb 18, 2025

Genprex advances diabetes gene therapy with new license - Investing.com India

Feb 18, 2025

Feb 18, 2025

Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq

Feb 18, 2025

Feb 14, 2025

Genprex faces Nasdaq delisting over stock price, equity issues - MSN

Feb 14, 2025

Feb 14, 2025

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace

Feb 14, 2025

Feb 13, 2025

Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq

Feb 13, 2025

Feb 13, 2025

Understanding GNPX’s financial ratios: A beginner’s guide - US Post News

Feb 13, 2025

Feb 13, 2025

Major Cancer Treatment Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer - Stock Titan

Feb 13, 2025

Feb 12, 2025

Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada

Feb 12, 2025

Feb 06, 2025

Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World

Feb 06, 2025

Feb 05, 2025

GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle

Feb 05, 2025

Jan 24, 2025

Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register

Jan 24, 2025

Jan 24, 2025

Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena

Jan 24, 2025

Jan 23, 2025

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire

Jan 23, 2025

Jan 15, 2025

Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World

Jan 15, 2025

Jan 14, 2025

Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance

Jan 14, 2025

Jan 06, 2025

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Jan 06, 2025

Dec 20, 2024

SEC Form 424B5 filed by Genprex Inc. - Quantisnow

Dec 20, 2024

Dec 18, 2024

Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World

Dec 18, 2024

Dec 16, 2024

Genprex advances to phase 2 in lung cancer trial - Investing.com

Dec 16, 2024

Dec 16, 2024

Genprex's Reqorsa Advances to Phase 2 After Successful Safety Trial in Lung Cancer Treatment - StockTitan

Dec 16, 2024